Brief: Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash
03/08/2026 13:15
BRIEF-Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash Aug 3 (Reuters) - Altimmune Inc ALT.O:
ALTIMMUNE INITIATES PERFORMA PHASE 3 TRIAL OF PEMVIDUTIDE IN PATIENTS WITH MASH
ALTIMMUNE - 52-WEEK DATA READOUT FROM PERFORMA PHASE 3 TRIAL ANTICIPATED IN 2029
Source text: ID:nGNXy7NS8
Further company coverage: ALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave